scholarly journals Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam

2015 ◽  
Vol 49 (4) ◽  
pp. 284-293 ◽  
Author(s):  
K Husmann ◽  
M J E Arlt ◽  
P Jirkof ◽  
M Arras ◽  
W Born ◽  
...  
Shock ◽  
2002 ◽  
Vol 18 (Supplement) ◽  
pp. 22
Author(s):  
G Roche-Nagle ◽  
J H Harmey ◽  
R Casey ◽  
J Kelly ◽  
D Bouchier-Hayes

2015 ◽  
Vol 358 (1) ◽  
pp. 67-75 ◽  
Author(s):  
Nadia Rucci ◽  
Mattia Capulli ◽  
Ole K. Olstad ◽  
Patrik Önnerfjord ◽  
Viveka Tillgren ◽  
...  

HPB ◽  
2011 ◽  
Vol 13 (3) ◽  
pp. 153-157 ◽  
Author(s):  
Jill E. Shea ◽  
Kweon-Ho Nam ◽  
Natalya Rapoport ◽  
Courtney L. Scaife

2005 ◽  
Vol 93 (04) ◽  
pp. 779-786 ◽  
Author(s):  
Buddy Setyono-Han ◽  
Jörg Stürzebecher ◽  
Wolfgang Schmalix ◽  
Bernd Muehlenweg ◽  
Anieta Sieuwerts ◽  
...  

SummaryThe serine protease uPA (urokinase-type plasminogen activator) and its receptor uPAR (CD87) are often elevated in malignant tumours, hence, inhibition of this tumour-associated plasminogen activation system provides an attractive target for therapeutic strategies. WX-UK1, a derivative of 3-aminophenylalanine in the L-conformation with inhibitory antiproteolytic properties, was tested for its specificity spectrum using specific chromogenic paranitroanilide peptide substrates. The corresponding D-enantiomer of WX-UK1 was used as a control. The anti-tumour and anti-metastatic (number of lung foci and weight of the axillary lymph nodes) properties were studied by subcutaneous administration of WX-UK1 to Brown Norwegian (BN) rats carrying orthotopically transplanted BN472 rat breast tumours. WX-UK1 selectively inhibited tumour-related proteases from rats and humans such as uPA, plasmin, or thrombin in the sub or low micromolar range. The activity was stereoselective as the D-enantiomer of WX-UK1 inhibited uPA and plas-min at approximately 70-fold higher Ki values than the active L-form. Chronical administration of the L-enantiomer of WXUK1 impaired primary tumour growth and metastasis of BN472 rat breast cancer in a dose-dependent manner. The minimum inhibitory dosage with maximal effect was between 0.15 and 0.3 mg/kg/day. The inactive D-enatiomer of WX-UK1 was not active in this respect. Daily treatment with WX-UK1 for up to 35 days was well tolerated as judged by the unchanged body and organ weight development. In conclusion, our results provide evidence that WX-UK1 as a single agent inhibits breast tumour growth and metastasis in vivo, and thus is a promising candidate drug to treat human cancer.


2013 ◽  
Vol 10 (82) ◽  
pp. 20130011 ◽  
Author(s):  
Jacob G. Scott ◽  
David Basanta ◽  
Alexander R. A. Anderson ◽  
Philip Gerlee

Two models of circulating tumour cell (CTC) dynamics have been proposed to explain the phenomenon of tumour ‘self-seeding’, whereby CTCs repopulate the primary tumour and accelerate growth: primary seeding, where cells from a primary tumour shed into the vasculature and return back to the primary themselves; and secondary seeding, where cells from the primary first metastasize into a secondary tissue and form microscopic secondary deposits, which then shed cells into the vasculature returning to the primary. These two models are difficult to distinguish experimentally, yet the differences between them is of great importance to both our understanding of the metastatic process and also for designing methods of intervention. Therefore, we developed a mathematical model to test the relative likelihood of these two phenomena in the subset of tumours whose shed CTCs first encounter the lung capillary bed, and show that secondary seeding is several orders of magnitude more likely than primary seeding. We suggest how this difference could affect tumour evolution, progression and therapy, and propose several possible methods of experimental validation.


PLoS Genetics ◽  
2018 ◽  
Vol 14 (2) ◽  
pp. e1007167 ◽  
Author(s):  
Kyra Campbell ◽  
Gaëlle Lebreton ◽  
Xavier Franch-Marro ◽  
Jordi Casanova

Sign in / Sign up

Export Citation Format

Share Document